The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.
 
Myung-Ju Ahn
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novacea
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis
 
D. Ross Camidge
Honoraria - ARIAD
Research Funding - ARIAD
 
Marcello Tiseo
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Otsuka; Pierre Fabre
Research Funding - ARIAD
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; Boehringer Ingelheim; Euclises; Nektar
Research Funding - Adaptimmune (Inst); ARIAD (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Eisai (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Xcovery (Inst)
 
Karin Holmskov Hansen
Honoraria - Novartis
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; MSD
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer
 
Sang-We Kim
No Relationships to Disclose
 
Rudolf M. Huber
Honoraria - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Pfizer; Roche
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clovis Oncology; Lilly; Novartis; Roche
Research Funding - Pierre Fabre
 
Howard Jack West
Consulting or Advisory Role - ARIAD; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Guardant Health; Merck; Novartis
Speakers' Bureau - ARIAD; Genentech/Roche
 
Harry J.M. Groen
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Research Funding - Lilly (Inst); Roche (Inst)
 
Maximilian J. Hochmair
No Relationships to Disclose
 
Natasha B. Leighl
Research Funding - Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer
 
Scott N. Gettinger
Consulting or Advisory Role - ARIAD; Bristol-Myers Squibb; Janssen
Research Funding - ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Incyte; Pfizer; Roche/Genentech
 
Corey J. Langer
Honoraria - Bristol-Myers Squibb; Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Abbott Biotherapeutics; ARIAD; Bayer/Onyx; Bristol-Myers Squibb; Cancer Support Community; Celgene; Clarient; Clovis Oncology; Genentech/Roche; Lilly/ImClone; Merck
Research Funding - Advantagene (Inst); Ariad (Inst); Celgene (Inst); Clovis Oncology (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Stem CentRx (Inst)
 
Luis G. Paz-Ares
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Lilly; MSD; Novartis; Pfizer; Roche
 
Egbert F. Smit
Consulting or Advisory Role - Lilly
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Roche/Genentech (Inst)
 
Edward S. Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Celgene; Lilly
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Celgene; Lilly
 
William Reichmann
No Relationships to Disclose
 
David Kerstein
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Dong-Wan Kim
No Relationships to Disclose